Effect of copulation on potentially precancerous prostate lesions, serum testosterone and prolactin levels in rats by Herrera-Covarrubias, D. et al.
Experimental Oncology 38, 73–79, 2016 (June) 73
EFFECT OF COPULATION ON POTENTIALLY PRECANCEROUS 
PROSTATE LESIONS, SERUM TESTOSTERONE AND PROLACTIN 
LEVELS IN RATS
D. Herrera-Covarrubias1, M.B. Tecamachaltzi-Silvaran2, M. Barradas-Moctezuma2, J.B. Rosales-Raya3, 
J. Manzo4, L.I. García4, G.E. Aranda-Abreu4, N. Ismail1, G.A. Coria-Avila4,*, M.E. Hernández4
1School of Psychology, University of Ottawa, Ottawa, ON K1N 6N5, Canada
2Doctorate in Brain Research, University of Veracruz, Xalapa, Veracruz 91190, Mexico
3Veterinary clinical laboratory, Xalapa, Veracruz 91190, Mexico
4Center for Brain Research, University of Veracruz, Xalapa, Veracruz 91190, Mexico
The prostate is an exocrine reproductive gland that participates in ejaculation and it is prone to diseases, including cancer. Aim: In the pre­
sent study, we assessed the long­term effects of copulation on the development of precancerous lesions in rats, and compared them with 
testosterone­induced prostatic lesions. Materials and Methods: One group of Wistar males was given 10 copulatory sessions to one ejacu­
lation with ovariectomized, hormone­primed females. Sessions occurred twice per week for a total of ten trials. A second group was exposed 
to females during the same trials, but physical contact was prevented. In addition, each group received a subcutaneous implant in the back 
either filled with testosterone propionate (T, 100 mg/kg) or empty. This resulted in four subgroups: 1) Control + No sex, 2) Control + Sex, 
3) T + No sex and 4) T + Sex. Two days after the 10th trial all the males were sacrificed for prostate histo logy (H&E) and hormone analy­
sis (testosterone and prolactin). Results: Males from the group Control + No sex expressed normal histo logy. However, those in the groups 
Control + Sex and T + No sex expressed metaplasia and dysplasia in both the dorsolateral and ventral portions of the prostate, respec­
tively. Interestingly, males from the group T + Sex expressed dysplasia in the dorsolateral prostate only, but not in the ventral prostate. 
Conclusions: These results indicate that constant copulation may facilitate the development of prostatic lesions in males with normal levels 
of testosterone. However, copulation induces less lesions in the ventral prostate of males treated with testosterone.
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Prostate cancer (CaP) is among all types of tumors 
in men the second most common worldwide and 
every year up to 7% of all the new cases may result 
in death [1]. The probability to develop CaP increases 
with age (> 65) [2], race (> African-ancestry) [3], diet 
(> high-fat products) [4], obesity (body mass index 
> 25) [5], smoking [6], and alterations in the level 
of hormones such as testosterone [7, 8] and prolactin 
(PRL) [9, 10]. Consequently, efforts are made world-
wide to understand its etiology and other possible 
contributing factors. For instance, there is no clear 
evidence about the role of sexual behavior in the de-
velopment of precancerous and cancerous prostatic 
lesions, although some studies in the past argued 
a probable link between copulation and CaP [11–14]. 
For example, in the 1960’s it was observed that ever-
married men expressed higher mortality rates of CaP 
than single men in the United States [13]. In other 
studies, the number of cases of CaP was positively 
correlated with the number of sexual partners [15] 
and with high coital frequency [16]. Michalek et al. [17] 
described a probable effect of celibacy on the pre-
vention of CaP. They analyzed more than 1000 death 
certificates of Catholic clergymen in New York from 
1965 to 1977 and found fewer cases of CaP as com-
pared to a matched control group of the same age. 
Although mortality was only 1% less in the celibate 
group the authors reported significant differences. 
However, other studies have shown either no effect 
of copulation on CaP or a positive effect. Kaplan [12] 
reported that mortality ratios of putative celibate 
priests resembled that of a population with a high al-
cohol and caloric intake but a relatively low exposure 
to tobacco. The study did not discard the possibility 
that celibacy had a protective effect for CaP, but ar-
gued that the evidence to suggest so was too weak. 
More recent evidence from a study with controls and 
cohorts argued that copulation protects the prostate 
from CaP [14]. Such studies provide ambiguous 
evidence to support any hypothesis about the role 
of copulation on prostate health.
As mentioned above, precancerous or cancerous 
lesions in the prostate have also been related to abnor-
mal levels of testosterone and PRL [7–10]. Copulation 
increases the levels of serum testosterone [18, 19] and 
PRL [20, 21] in both humans and laboratory rats. In ad-
dition, ejaculation increases the levels of androgen 
receptors (AR) and mRNA for AR in the prostate [22]. 
Testosterone can induce cell division and spontaneous 
mutations that result in more and abnormal cells within 
the gland [7, 8]. Similarly, PRL can activate molecular 
pathways (i.e. Jak2-Stat5a/b) that may result in tumor-
igenesis and progression to CaP [23]. Indeed, it has 
been shown that rats that receive systemic treatment 
with either testosterone or PRL during 4 weeks or more 
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will express precancerous lesions of the prostate (i.e. 
dysplasia) [9]. Accordingly, copulation per se induces 
short-term endocrine changes that might function 
as a long-term risk factor for the development of pre-
cancerous lesions. However, this has not been shown 
experimentally in an animal model. Thus, the aim of the 
present study was to assess the effects of repeated 
copulation to ejaculation on the development of pre-
cancerous prostatic lesions (i.e. dys plasia) in adult 
male rats. Our first hypothesis stated that constant 
copulation during 5 weeks would induce histological 
lesions comparable to those observed in males ex-
posed to exogenous systemic testosterone during 
the same period. In addition, we hypothe sized that the 
baseline blood levels of testosterone and PRL would 
be higher in male rats allowed to copulate constantly.
MATERIALS AND METHODS
Animals. We used 20 Wistar males and 10 females 
(Rattus norvegicus albinus). They were purchased 
from a certified laboratory animal supplier in Mexico 
(Circulo ADN) and were 8 weeks old and sexually na-
ïve at the start of the study. They were group-housed 
in large plexiglas cages (50 × 30 × 20 cm), and kept 
in a colony room at the Center for Brain Research, 
University of Veracruz, Mexico, in a 12–12 h reverse 
Light-Dark cycle (lights off at 8:00 hrs). Water and 
commercial feed (Rismart rat chow) were provided 
ad libitum. All the experimental procedures were car-
ried out according to the Official Mexican Norm NOM-
062-ZOO-1999 for use and care of laboratory animals.
Surgery and hormone treatments. One week 
before the start of copulatory trials all the males were 
randomly organized in two main groups, depending 
on the treatment they received at 8 weeks of age. 
The testosterone group (T) was implanted subcutane-
ously (s.c.) in the back with a silastic tube (Dow Corning 
Corp 25 mm length, 1.57 mm I.D. × 3.18 mm O.D.), con-
taining solid testosterone propionate (Sigma-Aldrich). 
This resulted in approximately 100 mg/kg of body weight 
as previously used in other studies [9, 24]. A second 
group served as control and was exposed to the same 
procedures, but the silastic tube was empty. Surgical 
implantation was done under inhaled halothane anes-
thesia, and took less than 3 min for each rat. After confir-
mation of deep anesthesia we performed a 10 mm skin 
incision on the lower back. A surgical probe was inserted 
s.c. and it was moved rostrally to separate the skin from 
the muscle. The silastic tube was slided in and pushed 
up to be placed at the upper back, between the two 
scapulae. The lower back incision was sutured and the 
rat was allowed to fully recover before it was placed 
back into its home cage. Early studies showed that 
these silastic capsules release testosterone at a rate of 
~30 µg/day/cm [25]. Both groups (T and Control) were 
further divided in two subgroups, depending on whether 
or not they were allowed to engage in sexual behavior 
to ejaculation. This resulted in four subgroups: 1) T + 
Sex (n = 5), 2) T + No sex (n = 5), 3) Control + Sex (n = 5), 
and 4) Control + No sex (n = 5).
The stimulus females were ovariectomized (OVX) 
and primed fully with s.c. injections of estradiol benzo-
ate (10 µg) 48 h and progesterone (500 µg) 4 h before 
each copulatory trial. For ovariectomy, females were 
anesthetized with a mixture of ketamine hydrochloride 
(50 mg/ml) and xylazine hydrochloride (4 mg/ml), 
mixed at a ratio of 4:3, respectively, injected intra-
peritoneally in a volume of 1 ml/kg of body weight. 
Anesthetized females were then OVX bilaterally via 
a lumbar incision. Post-surgical treatment for females 
included 3 days of s.c. injections of flunixin meglumine 
(2.5 mg/kg) for analgesia, and enrofloxacin (5 mg/kg) 
every 24 h to prevent post-surgical bacterial infections. 
All females were given a week of post-surgical recovery 
before they were used as sexual partners.
Sexual behavior. One week after the surgical im-
plantation of the silastic tubes (T or Control), the males 
started the first copulatory trial. Thus, the subgroups 
T + Sex and Control + Sex were allowed to copulate 
twice a week with the OVX sexually receptive female 
for a total of 10 trials (5 weeks of sexual activity). 
Subgroups T + No sex and Control + No sex were 
also exposed to a sexually receptive female behind 
a wiremesh that prevented copulation, but allowed 
visual, olfactory and acoustic stimulation. Each copu-
latory trial occurred in squared chambers (39 × 21 × 
21 cm) in which males were allowed to interact freely 
with the female until the first ejaculation was observed. 
Males were gently removed from the chamber one 
minute after ejaculation or after 60 min in case that 
ejaculation did not occur. The number of males that 
ejaculated in each trial and the ejaculation latency 
were recorded.
Prostate samples and histology. Two days after 
the 10th copulatory session the rats were anesthetized 
with sodium pentobarbital (35 mg/kg intraperitoneally). 
Then 3 ml of blood were obtained by cardiac puncture 
for hormone analysis (see Hormone measurements for 
further details). Anesthetized rats were then sacrificed 
with an overdose of sodium pentobarbital (120 mg/kg). 
An abdominal incision was performed and the acces-
sory sexual organs were carefully removed and placed 
into a container with 0.9% saline solution. The prostate 
was identified under a dissecting microscope (MEJI, 
EMZ-TR) and the gland was further divided into ventral 
(VP) and dorsolateral (DLP) prostate. The VP and DLP 
were soaked in formol 10% during 24 h, then dehy-
drated in alcohol 70% and 80% (1 h each), and 95% 
(3 × 2 h each), and ethanol 100% overnight, plus two 
more changes (1 h each), the following day. Then xylene 
(3 × 1 h each) was added, always with constant shaking. 
Tissue was embedded in paraffin wax 2 × 2 h each), 
sliced (5 µm thick) with a microtome (RM 2125RT Leica), 
mounted on slides in a bath at 52 °C (containing pork 
skin-based gelatin 2.5 mg/100 ml) and then processed 
for hematoxylin and eosin (H&E) dye technique as fol-
lows: 1 h at 57 °C, deparaffinization in xylene (3 × 5 min 
each), rehydration in alcohol/xylene (1:1) 5 min, ethanol 
96% 3 min, hematoxylin (10 min), water (30 s), acid al-
cohol (quick immersion), water (10 s), lithium carbonate 
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(30 s), water (10 s), eosin (4 quick immersions), dehy-
dration in ethanol 96% (3 min), ethanol 100% (2 min), 
ethanol/xylene 1:1 (2 min), and xylene (5 min). Then 
Permount was added and slides were coverslipped, air 
dried, and observed under a light microscope (Olym-
pus Ax70). Photomicrographs were taken at 40× and 
analyzed by the same experimenters. As in the previous 
study [9], we assessed prostate histology from normal 
to abnormal by taking into consideration the following 
histological features: 1) epithelium form (cubic in DLP, 
columnar in VP, vs hyperplasia, metaplasia, dysplasia, 
cancer in situ), 2) epithelium size (even vs anisocytosis), 
3) epithelium papillae (scarce vs plenty), 4) interstice 
space (even vs compressed), 5) interstice content (col-
lagen vs mononuclear), 6) nucleus size (even vs aniso-
kariosis), 7) nucleus location (basal cell polarity vs non 
basal), 8) nucleus to cytoplasm ratio N:C (1:2 vs 1:1), 
9) myoepithelium (euplasia vs proplasia), 10) pat-
tern observed at 4× (tubular vs cribiform), 11) lumen 
content (amorphous vs granular), and 12) chromatin 
(heterochromatin vs euchromatin). A blind score was 
performed by researchers and veterinarians for each 
prostate sample. Accordingly, the experimenters did not 
know to what subgroup of rats belonged each analyzed 
gland at the moment of diagnosis.
Hormones measurement. The hormones tes-
tosterone and PRL were measured in blood serum 
exclusively two days after the 10th copulatory session. 
Namely, on the same day the prostate was obtained. 
Blood was collected in vacutainer tubes containing 
no anticoagulant and incubated in upright position 
at room temperature for 30 min to allow clotting. Tubes 
were centrifuged for 15 min at 1000 r.p.m. Supernatant 
was aspirated at room temperature and serum was 
kept in 500 µl aliquots and frozen at −20 °C during 
few days until processing. We used an enzyme-linked 
immunosorbent assay (ELISA) and commercial kits 
for testosterone (ALPCO 11-TESHU-E01) and PRL 
(ALPCO 55-PRLRT-E01) and instructions were fol-
lowed as indicated by the supplier. The assays were 
read in an IMARK microplate reader with the software 
microplate manager from Bio-Rad.
Variables and statistical analysis. 1) Behavior: 
The ejaculation latency (minutes) was analyzed with 
a two-way (hormone treatment x session) ANOVA. Sig-
nificant differences were followed by a Fisher LSD 
posthoc test. The proportion of ejaculators for each 
session was also analyzed with a 2 × 2 contingency 
table (one-tailed Fisher exact probability test), con-
sidering the number of males that did (or did not) 
ejaculate. 2) Histology: We described 12 histological 
features in each male (See section Prostate samples 
and histo logy). 3) Hormones: Levels of testosterone 
and PRL (ng/mL) were analyzed with a non-parametric 
Kruskal — Wallis test, followed by Mann — Whitney 
tests to compare individual differences. All statisti-
cal analyses were performed using GraphPad Prism 
version 6.00 for Mac, GraphPad Software, La Jolla 
California USA, www.graphpad.com and the alpha 
level was set at p < 0.05.
RESULTS
Sexual behavior. With regard to the ejaculation 
latency the ANOVA failed to detect an interaction be-
tween hormone treatment × session F(9,72) = 0.46, 
p < 0.89, or a main effect of treatment F(1,8) = 0.02, p < 
0.88, but detected a main effect of session F(9,72) = 
2.03, p < 0.04. The posthoc analysis, however, did not 
detect specific differences between sessions (Fig. 1). 
The analysis of the number of ejaculators showed 
significant differences at session 1 (ejaculation was 
observed in 2 control vs 8 testosterone-treated males, 
p < 0.01), and at session 10 (ejaculation occurred 
in 10 control males vs 6 testosterone-treated, p < 
0.04), but not at sessions 2–9. These data indicated 
that rats from both groups reduced their ejaculation 
latency thro ughout the sessions. In addition, testos-
terone-treated males were more likely than controls 
to ejaculate at session 1, but less likely at session 
10 (Fig. 2).
0
10
20
30
40
50
60
70
1 2 3 4 5 6 7 8 9 10
M
ea
n 
+/
–S
EM
, m
in
Ejaculation latency
T
Control
Fig. 1. The ejaculation latency (minutes) of male rats during 
10 copulatory trials (5 weeks). Testosterone males received 
a subcutaneous implant in the back, filled with 100 mg/kg of tes-
tosterone propionate. Control males received an empty implant
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Fig. 2. Shows the proportion of males from Fig. 1 that ejaculated 
in each session. *Significant differences were detected between 
control and testosterone males at session 1 and 10
Prostate lesions induced by copulation or testoster-
one. In gene ral, the group Control + No sex expressed 
a normal (cubic) epithelium in the DLP, even in size 
(normal), with scarce papillae (normal). The interstitial 
space was even in size (normal) and contained collagen 
(normal). Interestingly, in 3 out of 5 rats the cell nuclei 
in the DLP were not homogeneous in size (anisokaryo-
sis), and expressed a relation N:C of 1:1 (normal > 1:2). 
Nevertheless, the nucleus had basal cell polarity (nor-
mal), the myoepithelium was euplastic (normal), with 
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Fig. 3. DLP (1) and VP (2) of rats divided in four subgroups: A — Control + No sex, B — Control + Sex, C — T + No sex, D — T + 
Sex. A1 — normal cubic epitheium (DLP), A2 — normal columnar epithelium, B1 — metaplasia, B2 — dysplasia, C1 — dysplasia, 
C2 — dysplasia, D1 — dysplasia, D2 — columnar
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tubular pattern (normal), amorphous content (normal), 
and there was heterochromatin, which is a less ac-
tive form of chromatin (Fig. 3, A1). In the same group 
(Control + No sex) 3/5 animals expressed a columnar 
epithelium (normal) in the VP, although some cases 
of anisocytosis were observed in 3/5 animals, and also 
expressed scarce papillae (normal). The interstitial 
space was even in size and contained colagen (normal). 
Nuclei were homogeneous in size (normal), with a basal 
cell polarity (normal), and a N:C of 1:2, and there was 
heterochromatin. The myoepithelium was euplasic and 
the pattern observed at 4× was tubular (Fig. 3, A2). Al-
though males from this subgroup (Control + No sex) had 
in general normal histological features, none of them 
expressed 100% of normal histology. For example, 
some males with normal epithelium’s form expressed 
what is considered abnormal epithelium’s size (aniso-
cytosis) or abnormal nucleus size (anisokaryosis), 
or modified N:C ratio (1:1). This suggests that even 
in a sample of putative healthy rats there is variability 
in the histological features of the prostate.
Rats from the subgroups Control + Sex, T + Sex 
and T + No sex displayed more histological abnormali-
ties in both the DLP and VP. Such differences and the 
number of males with normal or abnormal features can 
be observed in Fig. 3, B, C, D, and 4, a, b.
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Fig. 4. Effect of constant copulation on the proportion of males 
with normal or abnormal epithelium in (a) the DLP and (b) in VP
For instance, in the DLP the Control + Sex males 
displayed more cases of abnormal epithelium (must 
be cubic in DLP and columnar in VP), or more severely 
affected with dysplasia (considered precancerous). 
There were also cases of anisocytosis, compressed 
interstice, anisokaryosis, apolarity of the nucleus, pro-
plasia of myoepithelium (enlarged), cribriform pattern, 
granular content in lumen, and euchromatin (more ac-
tive form of chromatin). In the T + Sex and T + No sex 
subgroups there were more cases of epithelium dys-
plasia in the DLP. Interestingly, fewer cases of dysplasia 
were observed in the VP of T + Sex animals (Fig. 4, b).
Serum levels of testosterone and PRL. With re-
gard to testosterone, the Kruskal — Wallis test revealed 
significant differences between groups H(4,19) = 8.2, 
p < 0.05. The Mann — Whitney test indicated individual 
differences between the subgroups Control + No sex 
(Median = 0.38 ng/ml) vs Control + Sex (Median = 
2.05 ng/ml) U = 2, p < 0.05, and between Control + 
Sex (Median = 2.05 ng/ml) vs T + No sex (Median = 
0.21 ng/ml) U = 1, p < 0.05 (Fig. 5). With regard to PRL, 
the analysis failed to detect significant differences be-
tween groups: Control + No sex (Median = 20.86 ng/ml), 
Control + Sex (Median = 32.15 ng/ml), T + No sex (Me-
dian = 100.8 ng/ml) and T + Sex (Median = 21.22 ng/ml) 
H(4,18) = 3.02, p = 0.37.
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Fig. 5. Serum baseline levels of testosterone after 10 trials 
of copulation (5 weeks). Different letters indicate significant 
differences between bars
DISCUSSION
The results of the present study indicate that in rats 
repeated copulation induced histological alterations 
in both the DLP and VP (e.g. metaplasia and dysplasia). 
In the DLP the lesions were milder than those observed 
in sexually naïve males that received exogenous 
testosterone, but in the VP the effect of copulation 
and testosterone were comparable. Copulation plus 
exogenous testosterone had additional negative ef-
fects in the DLP as compared to testosterone without 
copulation, but in the VP such combination decreased 
the cases of dysplasia (see Fig. 4, a, b). The baseline 
levels of serum testosterone were higher in males 
with constant copulation, but not in males with s.c. 
implants filled with testosterone. We speculate that 
testosterone was increased during the first week 
of implant, but decreased subsequently via negative 
feedback mechanisms,  resulting in low levels after 
6 weeks. Such argument is possibly supported by the 
proportion of ejaculators observed in sessions 1 and 
10 (see Fig. 2). That is, more testosterone-treated 
males ejaculated at session 1 as compared to control 
males, but the opposite outcome occurred by the 
10th session. The results also indicate that the levels 
of serum PRL were not affected by either copulation 
or testosterone implants. Thus, we argue that prostate 
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lesions induced by constant copulation (5 weeks) are 
mainly due to the effects of increased testosterone.
Specific effects of copulation on prostate le-
sions. After 10 copulatory sessions 60% of males from 
the Control + Sex subgroup were affected. Two of them 
expressed in the DLP an epithelium with metaplasia 
(Fig. 3, B1) that is the reversible replacement of one 
differentiated cell type with another mature differenti-
ated cell type. Those rats also expressed anisocytosis 
(unequal abnormal size of epithelium cells) and plenty 
of papillae, which resulted in reduced interstices. In ad-
dition, cells started to express abnormal nuclear shape 
(anisokaryosis), which is one of the key diagnostic tools 
used in identifying cancerous cells [26, 27]. Further-
more, the nuclei were no longer polar, the N:C ratio 
was abnormal (1:1) and there was a cribriform pattern. 
Anysokaryosis, apolarity and alterations in N:C indicate 
changes in chromosome organization, which in turn can 
affect gene expression [28] that eventually may result 
in dysplasia (observed in one male). In the subgroups T 
+ No sex and T + Sex 80% of the rats expressed dysplasia 
in the DLP (Fig. 3, C1, D1), which refers to a precancerous 
lesion characterized by the presence of immature and 
abnormal epithelial cells with abnormal function. These 
changes indicate that in the DLP s.c. implants of testos-
terone (100 mg/kg) for periods as short as 5 weeks are 
more aggressive than the effects of copulation during the 
same period. Further experiments are required to confirm 
that testosterone is the only responsible of copulation-
induced prostatic lesions. In addition, it is important to fi-
gure out if a long resting period after constant copulation 
would result in a total recovery of the prostate.
Effects of copulation and testosterone on DLP 
and VP. As mentioned above, copulation affected the 
DLP and the combination of copulation plus exogenous 
testosterone resulted in more alterations. Males from 
the T + Sex subgroup expressed more cases of aniso-
cytosis, proplastic myoepithelium and apolar nuclei than 
males from the T + No sex subgroup. However, this was 
not observed in the VP. As a matter of fact, copulation 
plus exogenous testosterone resulted in fewer cases 
of dysplasia in the VP (see Fig. 4, b). Evidence indicates 
that ejaculation induces in the VP an acute increase 
in the levels of both AR and AR-mRNA [22]. However, 
it is not known whether such increase is maintained after 
5 weeks of constant copulation in rats. One speculation 
is that the opposite occurs after several copulatory tri-
als, namely that AR may be decreased and therefore 
VP may be less sensitive to exogenous testosterone. 
Like in rats, the human prostate is also heterogeneous 
with regard to its embryologic origin and histology [29]. 
Its three zones (periurethral, central and peripheral) 
contain different concentration of glands, conducts, 
and AR distribution as observed in cases of CaP [30]. 
Such heterogeneity may account for the different ef-
fects of copulation on prostatic lesions in humans.
Copulation affected both portions of the prostate 
(DLP and VP) of control males, but prevented dysplasia 
in the VP of those males that received exogenous tes-
tosterone. Accordingly, the frequency of copulation plus 
the le vels of serum testosterone may help to account 
the probability of prostatic lesions in VP of rats or in ho-
mologous prostatic areas in other species. For example, 
age 65+ is a risk factor to develop CaP in humans. At that 
age the blood levels of testosterone are decreased 
by more than 50% in some men [31–34]. Human 
prostatic areas homologous of rat VP should be more 
sensitivity to copulation-induced testosterone, which 
would result in higher risk of CaP in low-testosterone 
men. By contrast, the same homologous areas of men 
with higher levels of testosterone should be benefited 
by copulation. Indeed, recent evidence from a study 
with controls and cohorts for CaP showed a protective 
effect of copulation, which also correlated with higher 
levels of serum testosterone in the controls [14]. Some 
of the mechanisms to explain the effect of copulation 
on DLP and VP may involve the AR directly [35]. It re-
mains to be shown whether the AR gene may mutate 
or be amplified by repeated copulation so that the 
AR may respond to lower levels of androgens, or per-
haps to other hormones (i.e. PRL) [10, 36–38].
CONCLUSIONS
Either constant copulation or exogenous testoste-
rone resulted in histological alterations of the two pros-
tatic portions (DLP, VP) in rats. However, the combination 
of copulation plus exogenous testosterone affected 
mainly the DLP, and to a much less extent the VP. This sug-
gests a bimodal effect of copulation in the VP, depending 
on the levels of serum testosterone. Accordingly, the 
celibacy theory may be supported in males with normal 
or low levels of testosterone, but would not be supported 
in males with higher-than-normal levels of testosterone. 
Further research is needed for understanding the specific 
role of copulation at long-term on the levels of AR in the 
VP and the development and maintenance of prostatic 
diseases, including cancer [39, 40].
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